The company has also developed two liquid biopsy cancer test, Liquid GPS Core for DNA and Liquid GPS Expression for RNA.
Sophia Genetics has received a CE-IVD mark for a sequencing-based test that, combined with data analytics, is meant to improve detection of leukemia.
The financing will be used to advance the firm's drug discovery platform, which combines high-throughput wet lab experimentation with artificial intelligence.
UgenTec will develop artificially intelligent software to support interpretation of MDxHealth's ConfirMDx and SelectMDx molecular prostate cancer tests.
Rhythm is using WuXi's artificial intelligence capabilities to support drug development targeting pathways associated with genetic obesity syndromes.
Three-month-old health data integrator Datavant hopes its analytics technology can improve the speed and success of clinical trials.
The companies are planning to develop individual disease diagnostics, and then a universal diagnostic from a single blood test.
The companies plan to combine their expertise in artificial intelligence and genomic data analyses to develop new precision medicine tools.
The Boston-based hospitals will provide Berg access to clinically annotated patient-derived specimens to track neurological disease pathology and develop diagnostic tools.
PreventionGenetics will use FDNA's technology to expand the diagnostic ability of its testing and interpretation services.
The Washington Post reports that a US Senate committee voted this week to approve the nomination of Stephen Hahn to lead the Food and Drug Administration.
Nature News reports that gene therapy approaches are tackling sickle cell disease, but that the cost of treatment is a concern.
One gene regulates hundreds of others to influence facial development, according to New Scientist.
In Nature this week: resources for single-cell analysis, little overlap in the microRNAs used by Salmonella and Shigella to infect host cells, and more.